Citigroup Inc Vor Biopharma Inc. Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in Vor Biopharma Inc. stock. As of the latest transaction made, Citigroup Inc holds 7,517 shares of VOR stock, worth $6,840. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,517

Previous 5,737 31.03%

Holding current value

$6,840

Previous $12,000 41.67%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.8 - $2.85 $3,204 - $5,073	1,780 Added 31.03%	7,517 $17,000
Q4 2023 Feb 09, 2024	BUY	$1.66 - $2.63 $9,493 - $15,040	5,719 Added 31772.22%	5,737 $12,000
Q3 2023 Nov 09, 2023	SELL	$2.1 - $3.35 $61,847 - $98,660	-29,451 Reduced 99.94%	18 $0
Q2 2023 Aug 10, 2023	SELL	$3.09 - $5.33 $177,526 - $306,219	-57,452 Reduced 66.1%	29,469 $91,000
Q1 2023 May 11, 2023	BUY	$4.68 - $6.96 $212,392 - $315,865	45,383 Added 109.26%	86,921 $467,000

Q4 2022 Feb 09, 2023	BUY	$3.98 - $7.43 $163,546 - $305,313	41,092 Added 9213.45%	41,538 $276,000
Q3 2022 Nov 10, 2022	SELL	$4.36 - $5.52 $1,364 - $1,727	-313 Reduced 41.24%	446 $2,000
Q2 2022 Aug 10, 2022	SELL	$3.89 - $6.44 $6,492 - $10,748	-1,669 Reduced 68.74%	759 $4,000
Q1 2022 May 12, 2022	SELL	$6.04 - $12.23 $25,458 - $51,549	-4,215 Reduced 63.45%	2,428 $15,000
Q4 2021 Feb 10, 2022	BUY	$11.32 - $18.02 $50,690 - $80,693	4,478 Added 206.84%	6,643 $77,000
Q3 2021 Nov 10, 2021	BUY	$12.24 - $20.38 $26,499 - $44,122	2,165 New	2,165 $34,000

Others Institutions Holding VOR

# of Institutions

Shares Held

29M

Call Options Held

1.8K

Put Options Held

100

View Full List

About Vor Biopharma Inc.

Ticker VOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,056,300
Market Cap $34.6M
Description
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AM...

More about VOR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account